China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has accepted its market filing for the Category 1 product ecnoglutide. The targeted indication for this treatment is blood glucose control in adult patients with type 2 diabetes.
Ecnoglutide’s Therapeutic Potential and Clinical Trial Success
Ecnoglutide is a cAMP signaling biased, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated excellent therapeutic effects on type 2 diabetes and obesity patients. It has also shown a good safety and tolerability profile in completed Phase III regulatory trials in China. These trials have positioned ecnoglutide as a promising treatment option for patients with type 2 diabetes.
International Expansion with South Korea Rights Deal
In May of this year, Sciwind granted South Korea-based firm HK inno.N Corporation (KOSDAQ: 195940) development and commercialization rights to ecnoglutide in South Korea in a deal valued at USD 56 million. This strategic partnership expands the global reach of Sciwind’s innovative diabetes treatment and underscores the company’s commitment to improving diabetes management worldwide.-Fineline Info & Tech
Leave a Reply